These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29175151)

  • 21. Osimertinib: First Global Approval.
    Greig SL
    Drugs; 2016 Feb; 76(2):263-73. PubMed ID: 26729184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NICE approves osimertinib for advanced lung cancer.
    Burki TK
    Lancet Respir Med; 2016 Dec; 4(12):954. PubMed ID: 27814987
    [No Abstract]   [Full Text] [Related]  

  • 23. Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).
    Watanabe H; Ichihara E; Kano H; Ninomiya K; Tanimoto M; Kiura K
    Intern Med; 2017 Aug; 56(16):2195-2197. PubMed ID: 28781309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
    Szymański FM; Płatek AE; Dziadziuszko R; Łęgosz P; Palczewski P
    Kardiol Pol; 2018; 76(3):670. PubMed ID: 29558014
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.
    Skoulidis F; Papadimitrakopoulou VA
    Clin Cancer Res; 2017 Feb; 23(3):618-622. PubMed ID: 27821604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
    Mezquita L; Varga A; Planchard D
    Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Drug approval: Osimertinib as an adjuvant treatment of non-small cell lung carcinoma with EFGR mutation after complete resection].
    Chevassut D; Duchemann B
    Bull Cancer; 2021 Dec; 108(12):1072-1073. PubMed ID: 34702549
    [No Abstract]   [Full Text] [Related]  

  • 29. [Non-Small Cell Lung Cancer - Development of Parallel Mechanisms of Resistance].
    Moeller M; Siebolts U; Wickenhauser C; Schuette W
    Pneumologie; 2018 Jul; 72(7):503-506. PubMed ID: 29466812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Das M
    Lancet Oncol; 2017 Jun; 18(6):e310. PubMed ID: 28506557
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting EGFR in Lung Cancer: Current Standards and Developments.
    Díaz-Serrano A; Gella P; Jiménez E; Zugazagoitia J; Paz-Ares Rodríguez L
    Drugs; 2018 Jun; 78(9):893-911. PubMed ID: 29915896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
    Ohe Y; Imamura F; Nogami N; Okamoto I; Kurata T; Kato T; Sugawara S; Ramalingam SS; Uchida H; Hodge R; Vowler SL; Walding A; Nakagawa K
    Jpn J Clin Oncol; 2019 Jan; 49(1):29-36. PubMed ID: 30508196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
    Gyawali B; West HJ
    J Clin Oncol; 2021 Jan; 39(3):175-177. PubMed ID: 33275490
    [No Abstract]   [Full Text] [Related]  

  • 34. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
    Hochmair MJ; Morabito A; Hao D; Yang CT; Soo RA; Yang JC; Gucalp R; Halmos B; Wang L; Golembesky A; Märten A; Cufer T
    Future Oncol; 2018 Nov; 14(27):2861-2874. PubMed ID: 30336693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
    Jenkins S; Yang JC; Jänne PA; Thress KS; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd FA
    J Thorac Oncol; 2017 Aug; 12(8):1247-1256. PubMed ID: 28527899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
    Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok TSK; Yang JC; Hoyle C
    Clin Drug Investig; 2018 Apr; 38(4):319-331. PubMed ID: 29247383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.
    Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G
    Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA
    Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.